A Study to Evaluate the Safety, Tolerability and Efficacy of Intravenous TAK-573 as Part of Combination Therapy in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

• Status: Withdrawn
• Trial end date: 2023-11-10

Summary

The purpose of this study is to determine the safety, tolerability, and recommended phase 2 dose (RP2D) of TAK-573 when used with dexamethasone and in combination with bortezomib, pomalidomide, or cyclophosphamide, in participants with RRMM.

• Phase: Phase 1

Details

• Lead Sponsor: Takeda
• Treatments: Bortezomib; Cyclophosphamide; Dexamethasone; Pomalidomide